- Home
- CMA vs JAZZ Comparison
CMA vs JAZZ Comparison
Compare CMA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- JAZZ
- Stock Information
- Founded
- CMA 1849
- JAZZ 2003
- Country
- CMA United States
- JAZZ Ireland
- Employees
- CMA N/A
- JAZZ N/A
- Industry
- CMA Major Banks
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- JAZZ Health Care
- Exchange
- CMA Nasdaq
- JAZZ Nasdaq
- Market Cap
- CMA 7.1B
- JAZZ 6.1B
- IPO Year
- CMA N/A
- JAZZ 2007
- Fundamental
- Price
- CMA $55.97
- JAZZ $97.78
- Analyst Decision
- CMA Hold
- JAZZ Strong Buy
- Analyst Count
- CMA 20
- JAZZ 13
- Target Price
- CMA $62.95
- JAZZ $181.85
- AVG Volume (30 Days)
- CMA 1.8M
- JAZZ 1.3M
- Earning Date
- CMA 04-21-2025
- JAZZ 05-06-2025
- Dividend Yield
- CMA 5.06%
- JAZZ N/A
- EPS Growth
- CMA 4.95
- JAZZ 49.21
- EPS
- CMA 5.29
- JAZZ 7.51
- Revenue
- CMA $3,234,000,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- CMA $7.32
- JAZZ $7.60
- Revenue Next Year
- CMA $3.12
- JAZZ $3.47
- P/E Ratio
- CMA $10.61
- JAZZ $13.00
- Revenue Growth
- CMA N/A
- JAZZ 5.76
- 52 Week Low
- CMA $45.32
- JAZZ $95.49
- 52 Week High
- CMA $73.45
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- CMA 54.29
- JAZZ 33.01
- Support Level
- CMA $54.42
- JAZZ $97.50
- Resistance Level
- CMA $57.01
- JAZZ $120.67
- Average True Range (ATR)
- CMA 1.38
- JAZZ 4.33
- MACD
- CMA 0.55
- JAZZ -0.53
- Stochastic Oscillator
- CMA 84.96
- JAZZ 1.21
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.